Grufity logoGrufity logo
StocksFundsSearch Filings

Quest Diagnostics Inc Stock Research

DGX

133.77USD+1.08(+0.81%)Market Closed

Market Summary

USD133.77+1.08
Market Closed
0.81%

DGX Alerts

DGX Stock Price

DGX RSI Chart

DGX Valuation

Market Cap

15.0B

Price/Earnings (Trailing)

18.89

Price/Sales (Trailing)

1.56

EV/EBITDA

13.79

Price/Free Cashflow

17.34

DGX Price/Sales (Trailing)

DGX Profitability

Operating Margin

34.74%

EBT Margin

12.50%

Return on Equity

16.05%

Return on Assets

7.37%

Free Cashflow Yield

5.77%

DGX Fundamentals

DGX Revenue

Revenue (TTM)

9.6B

Revenue Y/Y

-10.72%

Revenue Q/Q

-0.09%

DGX Earnings

Earnings (TTM)

793.0M

Earnings Y/Y

-43.1%

Earnings Q/Q

100%

Price Action

52 Week Range

119.75158.34
(Low)(High)

Last 7 days

1.7%

Last 30 days

-8.9%

Last 90 days

-4.4%

Trailing 12 Months

-4.6%

DGX Financial Health

Current Ratio

1.22

Debt/Equity

0.68

Debt/Cashflow

0.43

DGX Investor Care

Buy Backs (1Y)

5.88%

Diluted EPS (TTM)

6.83

Peers (Alternatives to Quest Diagnostics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
73.0B
60.9B
-4.91% 25.24%
12.73
1.2
1.94% -15.77%
20.7B
14.8B
-2.77% -13.32%
16.22
1.39
-6.96% -52.35%
15.0B
9.6B
-8.90% -4.59%
18.89
1.56
-10.08% -57.84%
MID-CAP
9.9B
13.6B
-10.37% 3.84%
14.64
0.74
5.04% -26.87%
6.1B
4.4B
-5.92% 18.26%
22.47
1.4
8.15% -30.89%
5.2B
2.3B
3.17% 35.63%
86.23
2.28
2.85% -58.05%
5.0B
3.2B
-11.17% 9.89%
21.14
1.55
17.88% 19.62%
3.9B
4.8B
11.84% 2.65%
10.12
0.8
3.57% -4.88%
2.9B
482.2M
34.10% -27.10%
-4.41
5.98
23.29% -70.12%
2.5B
2.2B
0.86% -34.14%
22.43
1.13
0.55% -41.23%
SMALL-CAP
1.7B
1.5B
6.01% 44.82%
-126.07
1.14
10.24% -173.11%
645.6M
2.9B
-18.53% -39.08%
-3.53
0.22
7.97% -101.02%
111.6M
81.1M
-7.29% 3.62%
-3.17
1.38
-31.36% -11847.33%
52.2M
46.4M
22.05% -38.86%
-1.16
1.12
-3.55% -44.93%
28.0M
25.2M
-8.89% -21.14%
-25.78
1.11
1.33% -63.01%

Financials for Quest Diagnostics

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue-2.8%9,6039,88310,29410,58210,679
Cost Of Revenue-1.3%6,3646,4506,5936,6456,599
  S&GA Expenses0.7%1,8881,8741,7751,7381,745
Costs and Expenses-0.9%8,3838,4558,4658,4938,445
EBITDA-19.8%1,5341,9122,2032,688-
EBITDA Margin-16.4%0.16*0.19*0.21*0.25*-
Earnings Before Taxes-14.2%1,0601,2351,6281,9312,425
EBT Margin-21.0%0.12*0.16*0.18*0.23*-
Interest Expenses1.4%-136-138-143-148-150
Net Income-16.2%7939461,2351,4841,881
Net Income Margin-20.2%0.10*0.12*0.14*0.18*-
Free Cahsflow-10.2%1,3141,4641,5521,602-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-0.3%12,79412,83713,22313,31213,442
  Current Assets-4.4%1,8141,8982,3342,4262,475
    Cash Equivalents-44.4%175315700790712
  Inventory-1.0%190192183187197
  Net PPE1.6%1,7951,7661,7071,6641,668
  Goodwill0.3%7,2417,2207,1907,1957,197
  Current Liabilities-12.6%1,3551,5511,6021,5771,700
  Long Term Debt-0.1%3,9753,9783,9803,9833,985
    LT Debt, Current0%2.002.002.002.002.00
Shareholder's Equity2.7%6,0505,8936,2356,4506,415
  Retained Earnings1.5%8,4128,2908,2638,0837,926
  Additional Paid-In Capital-1.3%2,2662,2952,2722,2502,226
Shares Outstanding-3.4%112116117119-
Minority Interest2.7%38.0037.0037.0039.0038.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-22.5%1,3321,7181,8651,9241,982
  Share Based Compensation7.8%83.0077.0074.0077.0079.00
Cashflow From Investing2.0%-532-543-596-574-55.00
Cashflow From Financing22.8%-1,337-1,732-1,556-1,120-2,445
  Dividend Payments0%305305307305308
  Buy Backs-26.5%1,0351,4081,2368622,162

Risks for DGX

What is the probability of a big loss on DGX?

58.5%


Probability that Quest Diagnostics stock will be more than 20% underwater in next one year

19.2%


Probability that Quest Diagnostics stock will be more than 30% underwater in next one year.

0%


Probability that Quest Diagnostics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does DGX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Quest Diagnostics was unfortunately bought at previous high price.

Drawdowns

Returns for DGX

Cumulative Returns on DGX

10.0%


10-Year Cumulative Returns

10.2%


7-Year Cumulative Returns

6.7%


5-Year Cumulative Returns

7.6%


3-Year Cumulative Returns

What are the long-term rolling returns for DGX?

FIve years rolling returns for Quest Diagnostics.

Annualized Returns

Which funds bought or sold DGX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-23
Brookfield Corp /ON/
added
31.47
1,068,140
6,721,570
0.03%
2023-05-23
MOUNTAIN PACIFIC INVESTMENT ADVISERS INC/ID
unchanged
-
-51,612
488,106
0.04%
2023-05-23
Front Row Advisors LLC
unchanged
-
-2,000
19,000
0.01%
2023-05-23
Toroso Investments, LLC
added
21.96
88,000
954,000
0.02%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-11.54
-29,214,500
116,864,000
0.04%
2023-05-22
PUTNAM INVESTMENTS LLC
reduced
-22.68
-126,746
294,703
-%
2023-05-22
FDx Advisors, Inc.
unchanged
-
-
1,682,000
0.07%
2023-05-22
Raleigh Capital Management Inc.
added
23.72
2,848
27,282
0.01%
2023-05-18
JPMORGAN CHASE & CO
added
379
158,778,000
206,310,000
0.03%
2023-05-18
SkyView Investment Advisors, LLC
new
-
-
-
-%

1–10 of 44

Latest Funds Activity

Are funds buying DGX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own DGX
No. of Funds

Quest Diagnostics News

MarketWatch
Illumina Inc. stock rises Friday, still underperforms market.
MarketWatch,
2 days ago
The Motley Fool
Investing.com India

Schedule 13G FIlings of Quest Diagnostics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
12.27%
13,973,339
SC 13G/A
Feb 07, 2023
state street corp
5.16%
5,879,980
SC 13G/A
Jan 23, 2023
blackrock inc.
10.9%
12,391,327
SC 13G/A
Apr 08, 2022
blackrock inc.
10.7%
12,807,624
SC 13G/A
Feb 10, 2022
state street corp
5.11%
6,268,789
SC 13G
Feb 07, 2022
blackrock inc.
9.5%
11,636,382
SC 13G/A
Feb 10, 2021
vanguard group inc
10.64%
14,337,685
SC 13G/A
Feb 01, 2021
blackrock inc.
8.5%
11,464,215
SC 13G/A
Feb 13, 2020
macquarie group ltd
0.20%
271,969
SC 13G/A
Feb 12, 2020
vanguard group inc
11.42%
15,394,930
SC 13G/A

DGX Fair Value

Quest Diagnostics fair value in different scenarios

The table shows the Fair Value estimates for Quest Diagnostics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

78.11

-41.61%

101.69

-23.98%

129.15

-3.45%

225.86

68.84%

311.56

132.91%
Current Inflation

72.87

-45.53%

93.46

-30.13%

116.75

-12.72%

198.93

48.71%

271.32

102.83%
Very High Inflation

66.25

-50.47%

83.29

-37.74%

101.79

-23.91%

167.42

25.16%

224.78

68.03%

Historical Quest Diagnostics Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Quest Diagnostics

View All Filings
Date Filed Form Type Document
May 19, 2023
3
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading

Latest Insider Trading transactions for DGX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-17
MAIN TIMOTHY L
acquired
-
-
1,369
-
2023-05-17
Gregg Vicky B
acquired
-
-
1,369
-
2023-05-17
Doi Tracey
acquired
-
-
1,369
-
2023-05-17
RING TIMOTHY M
acquired
-
-
1,369
-
2023-05-17
Lassiter Wright III
acquired
-
-
1,369
-
2023-05-17
MORRISON DENISE M
acquired
-
-
1,369
-
2023-05-17
Diaz Luis
acquired
-
-
1,369
-
2023-05-17
WILENSKY GAIL R
acquired
-
-
1,369
-
2023-05-17
PFEIFFER GARY M
acquired
-
-
1,369
-
2023-04-24
KUPPUSAMY KARTHIK
acquired
3,576
143
25.00
svp, clinical solutions

1–10 of 50

Stephen H. Rusckowski
49000
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

DGX Income Statement

2023-03-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]  
Net revenues$ 2,331$ 2,611
Operating costs and expenses and other operating income:  
Cost of services1,5601,646
Selling, general and administrative439425
Amortization of intangible assets2627
Other operating expense, net10
Total operating costs and expenses, net2,0262,098
Operating income305513
Other income (expense):  
Interest expense, net(35)(37)
Other income (expense), net7(24)
Total non-operating expense, net(28)(61)
Income before income taxes and equity in earnings of equity method investees277452
Income tax expense(65)(110)
Equity in earnings of equity method investees, net of taxes531
Net income217373
Less: Net income attributable to noncontrolling interests1518
Net income attributable to Quest Diagnostics$ 202$ 355
Earnings per share attributable to Quest Diagnostics’ common stockholders:  
Basic (in dollars per share)$ 1.80$ 2.97
Diluted (in dollars per share)$ 1.78$ 2.92
Weighted average common shares outstanding:  
Basic (in Shares)112119
Diluted (in Shares)113121

DGX Balance Sheet

2023-03-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Assets  
Cash and cash equivalents$ 175$ 315
Accounts receivable, net of allowance for credit losses of $30 as of both March 31, 2023 and December 31, 20221,2541,195
Inventories190192
Prepaid expenses and other current assets195196
Total current assets1,8141,898
Property, plant and equipment, net1,7951,766
Operating lease right-of-use assets589585
Goodwill7,2417,220
Intangible assets, net1,0771,092
Investments in equity method investees128132
Other assets150144
Total assets12,79412,837
Liabilities and Stockholders' Equity  
Accounts payable and accrued expenses1,1981,396
Current portion of long-term debt22
Current portion of long-term operating lease liabilities155153
Total current liabilities1,3551,551
Long-term debt3,9753,978
Long-term operating lease liabilities490489
Other liabilities809812
Commitments and contingencies
Redeemable noncontrolling interest7777
Quest Diagnostics stockholders’ equity:  
Common stock, par value $0.01 per share; 600 shares authorized as of both March 31, 2023 and December 31, 2022; 162 shares issued as of both March 31, 2023 and December 31, 202222
Additional paid-in capital2,2662,295
Retained earnings8,4128,290
Accumulated other comprehensive loss(18)(21)
Treasury stock, at cost; 50 and 51 shares as of March 31, 2023 and December 31, 2022, respectively(4,612)(4,673)
Total Quest Diagnostics stockholders' equity6,0505,893
Noncontrolling interests3837
Total stockholders' equity6,0885,930
Total liabilities and stockholders' equity$ 12,794$ 12,837